Pirtobrutinib
- Generic Name
- Pirtobrutinib
- Brand Names
- Jaypirca
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21F4N5O3
- CAS Number
- 2101700-15-4
- Unique Ingredient Identifier
- JNA39I7ZVB
- Background
Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation. Unlike BTK covalent inhibitors, such as ibrutinib, that bind to the cysteine 481 (Cys481) amino acid wi...
- Indication
Pirtobrutinib is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
- Associated Conditions
- Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma
- Associated Therapies
- -
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 58
- Registration Number
- NCT06721013
- Locations
- 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-09
- Last Posted Date
- 2024-09-09
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 249
- Registration Number
- NCT06588478
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
- Conditions
- Interventions
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Target Recruit Count
- 60
- Registration Number
- NCT06553872
- Locations
- 🇺🇸
Univ of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06522386
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Kerry Rogers
- Target Recruit Count
- 30
- Registration Number
- NCT06466122
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Pirtobrutinib in Combination With Rituximab in Newly Diagnosed Marginal Zone Lymphoma (R+Pirto in Newly Diagnosed MZL)
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 23
- Registration Number
- NCT06390956
- Locations
- 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Inhye Ahn
- Target Recruit Count
- 60
- Registration Number
- NCT06333262
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06263491
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT06258174
- Locations
- 🇺🇸
Labcorp Drug Development, Dallas, Texas, United States
Glofitamab with Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- C. Babis Andreadis
- Target Recruit Count
- 30
- Registration Number
- NCT06252675
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.